相关实验视频
Updated: Sep 11, 2025

11:21
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
19.8K
对心房动进行一线导管切除 - - 低于推剂量的抗不律性药物可能导致其劣势:随机对照性研究分析,比较切除与抗不律性药物的随机对照性研究
Nawar Alhourani1, Christian Ellermann1, Julian Wolfes1
1Department of Cardiology II: Electrophysiology, University Hospital Muenster, Muenster, Germany.
Trends in cardiovascular medicine
|August 13, 2025
概括
导管切除在心房动 (AF) 管理中优于一线抗失律药物. 许多药物试验使用低于最佳剂量或患者停止治疗,可能会扭曲结果.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
背景情况:
- 导管切除是心房动 (AF) 的关键治疗方法.
- 以前的研究表明,导管切除比抗不律性药物更有效,作为AF的第一线治疗.
- 有关药物剂量的充足性和先前试验中的坚持存在担忧.
研究的目的:
- 评估随机试验中使用的抗心律失常药物的剂量和坚持性,将其与一线AF治疗中的导管切除进行比较.
- 确定可能影响导管切除报告优势的因素.
主要方法:
- 我们对PubMed和Medline进行了系统的文献搜索.
- 确定并分析了比较一线抗心律失常药物治疗与AF导管切除的随机试验.
- 在包括的研究中评估了药物剂量和患者的坚持.
主要成果:
- 药物手臂中很大一部分患者 (20-43%) 接受了低于最佳剂量的弗莱卡因,普罗帕芬和索塔洛.
- 在2.5%至10.4%的患者中,早期停止治疗或不接受处方抗心律失常药物.
- 在导管切除手臂中,多达10%的患者接受了辅助抗失常药物治疗.
结论:
- 导管切除对抗心律失常药物的优势在第一线AF治疗中可能被高估,因为在比较试验中,药物剂量和服药程度低于最佳.
- 需要进一步的研究来确认AF管理的最佳治疗策略,考虑适当的药物治疗方案和患者的坚持.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Dysrhythmias VI: Management of Dysrhythmias
107
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
107
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
990
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
990
Cardiopulmonary Resuscitation IV: Pharmacological Management
77
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
77
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K

